Price to Book Value (P/BV)
since 2018
Paying user area
Try for free
Moderna Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Cash Flow Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Total Asset Turnover since 2018
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Moderna Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Moderna Inc., P/BV, long-term trends, calculation
| P/BV | = | Share price1, 2, 3 | ÷ | Book value per share1 (BVPS) | BVPS1 | = | Stockholders’ equity1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 24, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2020 | = | ÷ | = | ÷ | |||||||
| Mar 13, 2019 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Moderna Inc. Annual Report.
- Share Price
- The share price exhibited a significant upward trend from March 2019 to February 2021, increasing from $19.97 to a peak of $154.81. This peak was followed by a relatively stable period up to February 2022, with only a slight decrease to $151.33. Afterward, the share price showed a declining trajectory, falling to $139.26 in February 2023 and further down to $96.46 by February 2024.
- Book Value per Share (BVPS)
- BVPS experienced fluctuations over the analyzed period. Initially, it decreased from $4.65 in March 2019 to $3.19 in February 2020. Subsequently, it increased steadily, reaching $6.41 in February 2021, followed by a substantial rise to $35.11 in February 2022. The upward trend continued to $49.50 in February 2023 before declining to $36.26 in February 2024.
- Price-to-Book Value Ratio (P/BV)
- The P/BV ratio showed considerable volatility throughout the period. It started at 4.29 in March 2019, peaked at 24.16 in February 2021, indicating a strong market premium over book value. There was a sharp decrease in the following year to 4.31 in February 2022 and a continued decline to 2.81 in February 2023, stabilizing near 2.66 by February 2024. This suggests a market reassessment towards a valuation more closely aligned with the company’s book value.
Comparison to Competitors
Moderna Inc., P/BV, long-term trends, comparison to competitors
| Moderna Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2024 | |||||||||||||
| Feb 24, 2023 | |||||||||||||
| Feb 25, 2022 | |||||||||||||
| Feb 26, 2021 | |||||||||||||
| Feb 27, 2020 | |||||||||||||
| Mar 13, 2019 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Moderna Inc., P/BV, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Moderna Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 23, 2024 | ||
| Feb 24, 2023 | ||
| Feb 25, 2022 | ||
| Feb 26, 2021 | ||
| Feb 27, 2020 | ||
| Mar 13, 2019 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
Comparison to Industry (Health Care)
Moderna Inc., P/BV, long-term trends, comparison to industry (health care)
| Moderna Inc. | Health Care | |
|---|---|---|
| Feb 23, 2024 | ||
| Feb 24, 2023 | ||
| Feb 25, 2022 | ||
| Feb 26, 2021 | ||
| Feb 27, 2020 | ||
| Mar 13, 2019 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).